Cargando…
Acute hemorrhagic leukoencephalitis after administration of the first dose of ChAdOx1 nCoV-19 SARS-CoV-2 (COVISHIELD™) vaccine
BACKGROUND: Many central and peripheral nervous system complications, following COVID-19 vaccination, have been described. We report an unusual case of central demyelinating disorder, following the administration of the ChAdOx1 nCoV-19 SARS-CoV-2 (COVISHIELD™) vaccine. CASE-REPORT: The 28-year femal...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966115/ http://dx.doi.org/10.1016/j.nerep.2022.100089 |
_version_ | 1784678586261700608 |
---|---|
author | Rizvi, Imran Garg, Ravindra Kumar Gupta, Priyanka Malhotra, Hardeep Singh Kumar, Neeraj Uniyal, Ravi Pandey, Shweta |
author_facet | Rizvi, Imran Garg, Ravindra Kumar Gupta, Priyanka Malhotra, Hardeep Singh Kumar, Neeraj Uniyal, Ravi Pandey, Shweta |
author_sort | Rizvi, Imran |
collection | PubMed |
description | BACKGROUND: Many central and peripheral nervous system complications, following COVID-19 vaccination, have been described. We report an unusual case of central demyelinating disorder, following the administration of the ChAdOx1 nCoV-19 SARS-CoV-2 (COVISHIELD™) vaccine. CASE-REPORT: The 28-year female developed sudden onset headache followed by weakness of the left upper and lower limbs, and gait ataxia. Neurological symptoms developed two weeks after administration of the first dose of the ChAdOx1 nCoV-19 SARS-CoV-2 (COVISHIELD™) vaccine. Magnetic resonance imaging brain revealed T2/FLAIR hyperintense lesions involving bilateral subcortical white matter, splenium of the corpus callosum, and both cerebellar hemispheres. Few lesions showed blooming on gradient echo sequence suggestive of a hemorrhagic component. Post-contrast T1 images showed mild enhancement of demyelinating lesions. The patient was treated intravenously with methylprednisolone. After 12 weeks of follow-up, there was a substantial improvement in her symptoms. She became independent in all her activities of daily living. CONCLUSION: In conclusion, this is an unusual case of acute hemorrhagic leukoencephalitis following ChAdOx1 nCoV-19 SARS-CoV-2 (COVISHIELD™) vaccination. |
format | Online Article Text |
id | pubmed-8966115 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Author(s). Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89661152022-03-31 Acute hemorrhagic leukoencephalitis after administration of the first dose of ChAdOx1 nCoV-19 SARS-CoV-2 (COVISHIELD™) vaccine Rizvi, Imran Garg, Ravindra Kumar Gupta, Priyanka Malhotra, Hardeep Singh Kumar, Neeraj Uniyal, Ravi Pandey, Shweta Neuroimmunology Reports Article BACKGROUND: Many central and peripheral nervous system complications, following COVID-19 vaccination, have been described. We report an unusual case of central demyelinating disorder, following the administration of the ChAdOx1 nCoV-19 SARS-CoV-2 (COVISHIELD™) vaccine. CASE-REPORT: The 28-year female developed sudden onset headache followed by weakness of the left upper and lower limbs, and gait ataxia. Neurological symptoms developed two weeks after administration of the first dose of the ChAdOx1 nCoV-19 SARS-CoV-2 (COVISHIELD™) vaccine. Magnetic resonance imaging brain revealed T2/FLAIR hyperintense lesions involving bilateral subcortical white matter, splenium of the corpus callosum, and both cerebellar hemispheres. Few lesions showed blooming on gradient echo sequence suggestive of a hemorrhagic component. Post-contrast T1 images showed mild enhancement of demyelinating lesions. The patient was treated intravenously with methylprednisolone. After 12 weeks of follow-up, there was a substantial improvement in her symptoms. She became independent in all her activities of daily living. CONCLUSION: In conclusion, this is an unusual case of acute hemorrhagic leukoencephalitis following ChAdOx1 nCoV-19 SARS-CoV-2 (COVISHIELD™) vaccination. The Author(s). Published by Elsevier B.V. 2022 2022-03-30 /pmc/articles/PMC8966115/ http://dx.doi.org/10.1016/j.nerep.2022.100089 Text en © 2022 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Rizvi, Imran Garg, Ravindra Kumar Gupta, Priyanka Malhotra, Hardeep Singh Kumar, Neeraj Uniyal, Ravi Pandey, Shweta Acute hemorrhagic leukoencephalitis after administration of the first dose of ChAdOx1 nCoV-19 SARS-CoV-2 (COVISHIELD™) vaccine |
title | Acute hemorrhagic leukoencephalitis after administration of the first dose of ChAdOx1 nCoV-19 SARS-CoV-2 (COVISHIELD™) vaccine |
title_full | Acute hemorrhagic leukoencephalitis after administration of the first dose of ChAdOx1 nCoV-19 SARS-CoV-2 (COVISHIELD™) vaccine |
title_fullStr | Acute hemorrhagic leukoencephalitis after administration of the first dose of ChAdOx1 nCoV-19 SARS-CoV-2 (COVISHIELD™) vaccine |
title_full_unstemmed | Acute hemorrhagic leukoencephalitis after administration of the first dose of ChAdOx1 nCoV-19 SARS-CoV-2 (COVISHIELD™) vaccine |
title_short | Acute hemorrhagic leukoencephalitis after administration of the first dose of ChAdOx1 nCoV-19 SARS-CoV-2 (COVISHIELD™) vaccine |
title_sort | acute hemorrhagic leukoencephalitis after administration of the first dose of chadox1 ncov-19 sars-cov-2 (covishield™) vaccine |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966115/ http://dx.doi.org/10.1016/j.nerep.2022.100089 |
work_keys_str_mv | AT rizviimran acutehemorrhagicleukoencephalitisafteradministrationofthefirstdoseofchadox1ncov19sarscov2covishieldvaccine AT gargravindrakumar acutehemorrhagicleukoencephalitisafteradministrationofthefirstdoseofchadox1ncov19sarscov2covishieldvaccine AT guptapriyanka acutehemorrhagicleukoencephalitisafteradministrationofthefirstdoseofchadox1ncov19sarscov2covishieldvaccine AT malhotrahardeepsingh acutehemorrhagicleukoencephalitisafteradministrationofthefirstdoseofchadox1ncov19sarscov2covishieldvaccine AT kumarneeraj acutehemorrhagicleukoencephalitisafteradministrationofthefirstdoseofchadox1ncov19sarscov2covishieldvaccine AT uniyalravi acutehemorrhagicleukoencephalitisafteradministrationofthefirstdoseofchadox1ncov19sarscov2covishieldvaccine AT pandeyshweta acutehemorrhagicleukoencephalitisafteradministrationofthefirstdoseofchadox1ncov19sarscov2covishieldvaccine |